| Doxil/Caelyx |
PEGylated liposomal doxorubicin |
Myeloma, Kaposi’s sarcoma, breast, and ovarian cancer |
Approved in the US (1995) |
| DaunoXome |
liposomal daunorubicin |
Kaposi’s sarcoma |
Approved in the US (1996) |
| Myocet |
liposomal doxorubicin |
Breast cancer |
Approved in Europe/Canada (2000) |
| Abraxane |
albumin-bound paclitaxel |
Breast, non-small-cell lung, and pancreatic cancer |
Approved in the US (2005) |
| Lipusu |
liposomal paclitaxel |
Breast and non-small-cell lung cancer |
Approved in China (2006) |
| Oncaspar |
L-asparaginase conjugate |
Acute lymphoblastic leukemia |
Approved in the US (2006) |
| DepoCyt |
liposomal cytarabine |
Lymphoma, Leukemia |
Approved in the US (1999) |
| Genexol-PM |
paclitaxel micellar |
Breast, non-small-cell lung, ovarian, and gastric cancer |
Approved in Korea (2007) |
| Mepact |
liposomal mifamurtide |
Osteogenic sarcoma |
Approved in Europe (2009) |
| NanoTherm |
Iron oxide nanoparticles |
Brain tumors |
Approved in Europe (2011) |
| Marqibo |
Liposomal vincristine sulfate |
Acute lymphoblastic leukemia |
Approved in the US (2012) |
| ONIVYDE |
liposomal irinotecan |
Advanced pancreatic cancer |
Approved in the US (2015) |
| DHP107 |
paclitaxel lipid nanoparticles (oral administration) |
Gastric cancer |
Approved in Korea (2016) |
| Vyxeos |
liposomal daunorubicin and cytarabine |
High-risk acute myeloid leukemia |
Approved in the US (2017) |
| Apealea |
paclitaxel micellar |
Ovarian, peritoneal, and fallopian tube cancer |
Approved in Europe (2018) |
| Hensify |
hafnium oxide nanoparticles |
Locally-advanced soft tissue sarcoma |
Approved in Europe (2019) |
